Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia
NCT04638790Phase 3Recruiting
- Start
- Feb 2020
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label trial of doxorubicin, bleomycin, vinblastine, dacarbazine, etoposide and 3 more in classical Hodgkin lymphoma (cHL) (3 arms). Primary endpoints: Complete remission rate at 6 months, Acute Toxicity at 6 months and 3 more. Started Feb 2020; status: recruiting.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazineetoposide
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT04638790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04638790.